Study protocol of the FRENCH24-ANIS study: postoperative anti-infective strategy following pancreaticoduodenectomy in patients with preoperative biliary stents-an intergroup FRENCH-ACHBT-SFAR prospective randomized controlled trial.
Pancreaticoduodenectomy
/ adverse effects
Humans
Surgical Wound Infection
/ prevention & control
Antibiotic Prophylaxis
/ methods
Prospective Studies
Stents
Anti-Bacterial Agents
/ therapeutic use
France
/ epidemiology
Randomized Controlled Trials as Topic
Postoperative Complications
/ prevention & control
Male
Preoperative Care
/ methods
ANIS trial
Antibiotic therapy
Biliary drainage
FRENCH group
FRENCH24-ANIS
Pancreaticoduodenectomy
Surgical site infection
Journal
BMC surgery
ISSN: 1471-2482
Titre abrégé: BMC Surg
Pays: England
ID NLM: 100968567
Informations de publication
Date de publication:
22 Aug 2024
22 Aug 2024
Historique:
received:
21
01
2024
accepted:
16
07
2024
medline:
22
8
2024
pubmed:
22
8
2024
entrez:
21
8
2024
Statut:
epublish
Résumé
Despite advances in surgical techniques and care, pancreatoduodenectomy (PD) continues to have high morbidity and mortality rates. Complications such as sepsis, hemorrhage, pulmonary issues, shock, and pancreatic fistula are common postoperative challenges. A key concern in PD outcomes is the high incidence of infectious complications, especially surgical site infections (SSI) and postoperative pancreatic fistula (POPF). Bacteriobilia, or bile contamination with microorganisms, significantly contributes to these infections, increasing the risk of early postoperative complications. The occurrence of SSI in patients who undergo hepatobiliary and pancreatic (HPB) surgeries such as PD is notably higher than that in patients who undergo other surgeries, with rates ranging from 20 to 55%. Recent research by D'Angelica et al. revealed that, compared to cefoxitin, piperacillin/tazobactam considerably lowers the rate of postoperative SSI. However, these findings do not indicate whether extending the duration of antibiotic treatment is beneficial for patients at high risk of bacterial biliary contamination. In scenarios with a high risk of SSI, the specific agents, doses and length of antibiotic therapy remain unexplored. The advantage of prolonged antibiotic prophylaxis following PD has not been established through prospective studies in PD patients following biliary drainage. This is an intergroup FRENCH-ACHBT-SFAR multicenter, open-labelled randomized, controlled, superiority trial comparing 2 broad-spectrum antibiotic (piperacillin/tazobactam) treatment modalities to demonstrate the superiority of 5-day postoperative antibiotic therapy to antibiotic prophylaxis against the occurrence of surgical site infections (SSI) following pancreaticoduodenectomy in patients with preoperative biliary stents. The primary endpoint of this study is the overall SSI rate, defined according to the ACS NSQIP, as a composite of superficial SSI, deep incisional SSI, and organ/space SSI. In addition, we will analyze overall morbidity, antibiotic resistance profiles, the pathogenicity of bacteriological and fungal cocontamination, the impact of complications after bile drainage and neoadjuvant treatment on the bacteriological and fungal profile of biliculture and cost-effectiveness. This FRENCH24-ANIS study aims to evaluate 5-day post-operative antibiotic therapy combined with antibiotic prophylaxis on the occurrence of surgical site infections (SSI) following pancreaticoduodenectomy in patients with preoperative biliary stents. ClinicaTrials.gov number, NCT06123169 (Registration Date 08-11-2023); EudraCT number 2021-006991-18; EUCT Number: 2024-515181-14-00.
Sections du résumé
BACKGROUND
BACKGROUND
Despite advances in surgical techniques and care, pancreatoduodenectomy (PD) continues to have high morbidity and mortality rates. Complications such as sepsis, hemorrhage, pulmonary issues, shock, and pancreatic fistula are common postoperative challenges. A key concern in PD outcomes is the high incidence of infectious complications, especially surgical site infections (SSI) and postoperative pancreatic fistula (POPF). Bacteriobilia, or bile contamination with microorganisms, significantly contributes to these infections, increasing the risk of early postoperative complications. The occurrence of SSI in patients who undergo hepatobiliary and pancreatic (HPB) surgeries such as PD is notably higher than that in patients who undergo other surgeries, with rates ranging from 20 to 55%. Recent research by D'Angelica et al. revealed that, compared to cefoxitin, piperacillin/tazobactam considerably lowers the rate of postoperative SSI. However, these findings do not indicate whether extending the duration of antibiotic treatment is beneficial for patients at high risk of bacterial biliary contamination. In scenarios with a high risk of SSI, the specific agents, doses and length of antibiotic therapy remain unexplored. The advantage of prolonged antibiotic prophylaxis following PD has not been established through prospective studies in PD patients following biliary drainage.
METHODS
METHODS
This is an intergroup FRENCH-ACHBT-SFAR multicenter, open-labelled randomized, controlled, superiority trial comparing 2 broad-spectrum antibiotic (piperacillin/tazobactam) treatment modalities to demonstrate the superiority of 5-day postoperative antibiotic therapy to antibiotic prophylaxis against the occurrence of surgical site infections (SSI) following pancreaticoduodenectomy in patients with preoperative biliary stents. The primary endpoint of this study is the overall SSI rate, defined according to the ACS NSQIP, as a composite of superficial SSI, deep incisional SSI, and organ/space SSI. In addition, we will analyze overall morbidity, antibiotic resistance profiles, the pathogenicity of bacteriological and fungal cocontamination, the impact of complications after bile drainage and neoadjuvant treatment on the bacteriological and fungal profile of biliculture and cost-effectiveness.
CONCLUSION
CONCLUSIONS
This FRENCH24-ANIS study aims to evaluate 5-day post-operative antibiotic therapy combined with antibiotic prophylaxis on the occurrence of surgical site infections (SSI) following pancreaticoduodenectomy in patients with preoperative biliary stents.
TRIAL REGISTRATION
BACKGROUND
ClinicaTrials.gov number, NCT06123169 (Registration Date 08-11-2023); EudraCT number 2021-006991-18; EUCT Number: 2024-515181-14-00.
Identifiants
pubmed: 39169298
doi: 10.1186/s12893-024-02507-y
pii: 10.1186/s12893-024-02507-y
doi:
Substances chimiques
Anti-Bacterial Agents
0
Banques de données
ClinicalTrials.gov
['NCT06123169']
Types de publication
Journal Article
Clinical Trial Protocol
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
237Informations de copyright
© 2024. The Author(s).
Références
El Amrani M, Clement G, Lenne X, Farges O, Delpero JR, Theis D, et al. Failure-to-rescue in patients undergoing pancreatectomy: is hospital volume a standard for quality improvement programs? Nationwide analysis of 12,333 patients. Ann Surg. 2018;268(5):799–807.
doi: 10.1097/SLA.0000000000002945
pubmed: 30048329
Müssle B, Hempel S, Kahlert C, Distler M, Weitz J, Welsch T. Prognostic impact of bacterobilia on morbidity and postoperative management after pancreatoduodenectomy: a systematic review and meta-analysis. World J Surg. 2018;42(9):2951–62.
doi: 10.1007/s00268-018-4546-5
pubmed: 29464345
Ohgi K, Sugiura T, Yamamoto Y, Okamura Y, Ito T, Uesaka K. Bacterobilia may trigger the development and severity of pancreatic fistula after pancreatoduodenectomy. Surgery. 2016;160(3):725–30.
doi: 10.1016/j.surg.2016.03.032
pubmed: 27233637
Magill SS, O’Leary E, Janelle SJ, Thompson DL, Dumyati G, Nadle J, et al. Changes in prevalence of health care-associated infections in U.S. hospitals. N Engl J Med. 2018;379(18):1732–44.
doi: 10.1056/NEJMoa1801550
pubmed: 30380384
pmcid: 7978499
Collaborative GlobalSurg. Surgical site infection after gastrointestinal surgery in high-income, middle-income, and low-income countries: a prospective, international, multicentre cohort study. Lancet Infect Dis. 2018;18(5):516–25.
doi: 10.1016/S1473-3099(18)30101-4
Wu CC, Yeh DC, Lin MC, Liu TJ, P’eng FK. Prospective randomized trial of systemic antibiotics in patients undergoing liver resection. Br J Surg. 1998;85(4):489–93.
doi: 10.1046/j.1365-2168.1998.00606.x
pubmed: 9607529
Kondo K, Chijiiwa K, Ohuchida J, Kai M, Fujii Y, Otani K, et al. Selection of prophylactic antibiotics according to the microorganisms isolated from surgical site infections (SSIs) in a previous series of surgeries reduces SSI incidence after pancreaticoduodenectomy. J Hepatobiliary Pancreat Sci. 2013;20(3):286–93.
doi: 10.1007/s00534-012-0515-9
pubmed: 22481442
Sano S, Sugiura T, Kawamura I, Okamura Y, Ito T, Yamamoto Y, et al. Third-generation cephalosporin for antimicrobial prophylaxis in pancreatoduodenectomy in patients with internal preoperative biliary drainage. Surgery. 2019;165(3):559–64.
doi: 10.1016/j.surg.2018.09.011
pubmed: 30803620
Martin C, Auboyer C, Boisson M, Dupont H, Gauzit R, Kitzis M, et al. Antibioprophylaxis in surgery and interventional medicine (adult patients). Anaesth Crit Care Pain Med. 2019;38(5):549–62 Update 2017.
doi: 10.1016/j.accpm.2019.02.017
pubmed: 30836191
Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;70(3):195–283.
doi: 10.2146/ajhp120568
pubmed: 23327981
Donald GW, Sunjaya D, Lu X, Chen F, Clerkin B, Eibl G, et al. Perioperative antibiotics for surgical site infection in pancreaticoduodenectomy: does the SCIP-approved regimen provide adequate coverage? Surgery. 2013;154(2):190–6.
doi: 10.1016/j.surg.2013.04.001
pubmed: 23664266
D’Angelica MI, Ellis RJ, Liu JB, Brajcich BC, Gönen M, Thompson VM, et al. Piperacillin-Tazobactam Compared With Cefoxitin as Antimicrobial Prophylaxis for Pancreatoduodenectomy: A Randomized Clinical Trial. JAMA. 2023;329(18):1579.
doi: 10.1001/jama.2023.5728
pubmed: 37078771
pmcid: 10119777
Okamura K, Tanaka K, Miura T, Nakanishi Y, Noji T, Nakamura T, et al. Randomized controlled trial of perioperative antimicrobial therapy based on the results of preoperative bile cultures in patients undergoing biliary reconstruction. J Hepatobiliary Pancreat Sci. 2017;24(7):382–93.
doi: 10.1002/jhbp.453
pubmed: 28371248
Macedo FIB, Mowzoon M, Parikh J, Sathyanarayana SA, Jacobs MJ. Disparities in the management and prophylaxis of surgical site infection and pancreatic fistula after pancreatoduodenectomy. J Hepatobiliary Pancreat Sci. 2017;24(5):268–80.
doi: 10.1002/jhbp.443
pubmed: 28251830
Droogh DHM, Groen JV, de Boer MGJ, van Prehn J, Putter H, Bonsing BA, et al. Prolonged antibiotic prophylaxis after pancreatoduodenectomy: systematic review and meta-analysis. Br J Surg. 2023;110(11):1458–66.
doi: 10.1093/bjs/znad213
pubmed: 37440361
pmcid: 10564402
Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56–66.
doi: 10.1016/S1473-3099(18)30605-4
pubmed: 30409683
pmcid: 6300481
Kourbeti I, Kamiliou A, Samarkos M. Antibiotic Stewardship in Surgical Departments. Antibiotics. 2024;13(4):329.
doi: 10.3390/antibiotics13040329
pubmed: 38667005
pmcid: 11047567
Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital infection control practices advisory committee. Infect Control Hosp Epidemiol. 1999;20(4):250–78 quiz 279‑80.
doi: 10.1086/501620
pubmed: 10219875
Clark L, Burke L, Margaret Carr R, Coleman E, Roberts G, Torgerson DJ. A review found small variable blocking schemes may not protect against selection bias in randomized controlled trials. J Clin Epidemiol. 2022;141:90–8.
doi: 10.1016/j.jclinepi.2021.09.009
pubmed: 34520850
Schulz KF, Grimes DA. Unequal group sizes in randomised trials: guarding against guessing. Lancet. 2002;359(9310):966–70.
doi: 10.1016/S0140-6736(02)08029-7
pubmed: 11918933
Lachin JM. Properties of simple randomization in clinical trials. Control Clin Trials. 1988;9(4):312–26.
doi: 10.1016/0197-2456(88)90046-3
pubmed: 3203523
Schwarz L, Bruno M, Parker NH, Prakash L, Mise Y, Lee JE, et al. Active surveillance for adverse events within 90 days: the standard for reporting surgical outcomes after pancreatectomy. Ann Surg Oncol. 2015;22(11):3522–9.
doi: 10.1245/s10434-015-4437-z
pubmed: 25694246
Schweizer ML, Cullen JJ, Perencevich EN, Vaughan Sarrazin MS. Costs associated with surgical site infections in veterans affairs hospitals. JAMA Surg. 2014;149(6):575–81.
doi: 10.1001/jamasurg.2013.4663
pubmed: 24848779
pmcid: 7393605
de Lissovoy G, Fraeman K, Hutchins V, Murphy D, Song D, Vaughn BB. Surgical site infection: incidence and impact on hospital utilization and treatment costs. Am J Infect Control. 2009;37(5):387–97.
doi: 10.1016/j.ajic.2008.12.010
pubmed: 19398246
Chikhladze S, Lederer AK, Kousoulas L, Reinmuth M, Sick O, Fichtner-Feigl S, et al. Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data. World J Surg Onc. 2019;17(1):185.
doi: 10.1186/s12957-019-1732-3
Fukami Y, Maeda A, Takayama Y, Takahashi T, Uji M, Kaneoka Y. Adverse oncological outcome of surgical site infection after liver resection for colorectal liver metastases. Surg Today. 2019;49(2):170–5.
doi: 10.1007/s00595-018-1715-y
pubmed: 30225661
Scheufele F, Aichinger L, Jäger C, Demir IE, Schorn S, Sargut M, et al. Effect of preoperative biliary drainage on bacterial flora in bile of patients with periampullary cancer. Br J Surg. 2017;104(2):e182-8.
doi: 10.1002/bjs.10450
pubmed: 28121036
Mentor K, Ratnayake B, Akter N, Alessandri G, Sen G, French JJ, et al. Meta-analysis and meta-regression of risk factors for surgical site infections in hepatic and pancreatic resection. World J Surg. 2020;44(12):4221–30.
doi: 10.1007/s00268-020-05741-6
pubmed: 32812136
Kone LB, Torres C, Banulescu M, Maker VK, Maker AV. Perioperative Broad-spectrum Antibiotics are Associated With Decreased Surgical Site Infections Compared to 1st–3rd Generation Cephalosporins After Open Pancreaticoduodenectomy in Patients With Jaundice or a Biliary Stent. Annals of Surgery [Internet]. 24 juill 2020 [cité 15 févr 2022];Publish Ahead of Print. Disponible sur: https://journals.lww.com/10.1097/SLA.0000000000004216
Degrandi O, Buscail E, Martellotto S, Gronnier C, Collet D, Adam JP, et al. Perioperative antibiotherapy should replace prophylactic antibiotics in patients undergoing pancreaticoduodenectomy preceded by preoperative biliary drainage. J Surg Oncol. 2019;120(4):639–45.
Okamura K, Tanaka K, Miura T, Nakanishi Y, Noji T, Nakamura T, et al. Randomized controlled trial of perioperative antimicrobial therapy based on the results of preoperative bile cultures in patients undergoing biliary reconstruction. J Hepatobiliary Pancreat Sci. 2017;24(7):382–93.
doi: 10.1002/jhbp.453
pubmed: 28371248
Sauvanet A, Boher JM, Paye F, Bachellier P, Sa Cuhna A, Le Treut YP, et al. Severe jaundice increases early severe morbidity and decreases long-term survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. J Am Coll Surg. 2015;221(2):380–9.
doi: 10.1016/j.jamcollsurg.2015.03.058
pubmed: 26206638
Tanaka K, Nakamura T, Imai S, Kushiya H, Miyasaka D, Nakanishi Y, et al. The use of broad-spectrum antibiotics reduces the incidence of surgical site infection after pancreatoduodenectomy. Surg Today. 2018;48(9):825–34.
doi: 10.1007/s00595-018-1658-3
pubmed: 29687153
Fathi AH, Jackson T, Barati M, Eghbalieh B, Siegel KA, Siegel CT. Extended perioperative antibiotic coverage in conjunction with intraoperative bile cultures decreases infectious complications after pancreaticoduodenectomy. HPB Surgery. 2016;2016:1–6.
doi: 10.1155/2016/3031749
Sudo T, Murakami Y, Uemura K, Hashimoto Y, Kondo N, Nakagawa N, et al. Perioperative antibiotics covering bile contamination prevent abdominal infectious complications after pancreatoduodenectomy in patients with preoperative biliary drainage. World J Surg. 2014;38(11):2952–9.
doi: 10.1007/s00268-014-2688-7
pubmed: 25022981
Cortes A, Sauvanet A, Bert F, Janny S, Sockeel P, Kianmanesh R, et al. Effect of bile contamination on immediate outcomes after pancreaticoduodenectomy for tumor. J Am Coll Surg. 2006;202(1):93–9.
doi: 10.1016/j.jamcollsurg.2005.09.006
pubmed: 16377502
Stecca T, Nistri C, Pauletti B, Greco A, Di Giacomo A, Caratozzolo E, et al. Bacteriobilia resistance to antibiotic prophylaxis increases morbidity after pancreaticoduodenectomy: a monocentric retrospective study of 128 patients. Updates Surg. 2020;72(4):1073–80.
doi: 10.1007/s13304-020-00772-z
pubmed: 32314259
Tortajada P, Sauvanet A, Truant S, Regenet N, Souche R, Benoist S, et al. Does fungal biliary contamination after preoperative biliary drainage increase postoperative complications after pancreaticoduodenectomy? Cancers (Basel). 2020;12(10):2814.
doi: 10.3390/cancers12102814
pubmed: 33007843
pmcid: 7599947
Takara D, Sugawara G, Ebata T, Yokoyama Y, Igami T, Nagino M. Preoperative biliary MRSA infection in patients undergoing hepatobiliary resection with cholangiojejunostomy: incidence, antibiotic treatment, and surgical outcome. World J Surg. 2011;35(4):850–7.
doi: 10.1007/s00268-011-0990-1
pubmed: 21327600